CAY10706 |
| Catalog No.GC40650 |
CAY10706 is a ligustrazine-curcumin hybrid that promotes intracellular reactive oxygen species accumulation preferentially in lung cancer cells.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1881270-27-4
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
CAY10706 is a ligustrazine-curcumin hybrid that promotes intracellular reactive oxygen species accumulation preferentially in lung cancer cells. It has been shown to inhibit the proliferation of drug-sensitive (A549 (IC50 = 2.19 µM), SPC-A-1 (IC50 = 3.12 µM), LTEP-G-2 (IC50 = 2.88 µM)) and drug-resistant (A549/DDP (IC50 = 0.6 µM)) lung cancer cells but demonstrates little effect on non-tumor lung epithelial-like cells (HBE (IC50 = 21.34 µM)). CAY10706 can suppress the thioredoxin reductase system and inhibit the NF-κB, Akt, and ERK signaling.
Average Rating: 5 (Based on Reviews and 20 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *